Pappas Capital is a global venture capital and commercial development firm that focuses its investments on next-generation life science, agriculture, and technology companies. Their strategy involves direct venture investments through Pappas Ventures, managing specialized investment funds, and collaborating with research universities to accelerate the development of scientific discoveries into commercial products.
80% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (80% of deals). Average disclosed round size is $53.8M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Solu Therapeutics | Series A | $41M | Apr 2025 |
 Horizon Quantum Computing | Series A | $18.1M | Apr 2023 |
 Plexium, Inc. | Growth | $102M | Feb 2022 |
 Reneo Pharmaceuticals | Series A | $50M | May 2019 |
| VVelosBio Inc. | Series A | $58M | Oct 2018 |
Top Co-Investors
DCVC2 shared
Eli Lilly and Company1 shared
Longwood Fund1 shared
Astellas Venture Management1 shared
Alexandria Venture Investments1 shared
NEA (New Enterprise Associates)1 shared
RiverVest Venture Partners1 shared
SoftBank Vision Fund1 shared
Lux Capital1 shared
RA Capital Management1 shared
Surveyor Capital1 shared
The Column Group1 shared
Pivotal bioVenture Partners1 shared
M Ventures1 shared
CRV (Charles River Ventures)1 shared
Neotribe1 shared
Sofinnova Partners1 shared
Takeda Ventures, Inc.1 shared
Tencent Investment1 shared
Sequoia Capital1 shared
Last updated: 16 April 2026